What to Expect from Drug Prices Under the Latest Executive Order

In a continued push to bring down the cost of prescription drugs, President Donald Trump issued an executive order on May 12 aimed at aligning U.S. drug prices with those paid by other countries. The move has sparked debate about its potential effectiveness and whether it will lead to real change for American consumers.

The order, according to KFF Health News, has the potential to lower prices by as much as 30 to 80 percent, but it comes with several hurdles. The process is unlikely to move quickly, and there are still questions about whether the executive branch has the legal power to enforce such pricing changes.

Under the order, the administration calls for a “most-favored-nation” pricing model. This means drug manufacturers would be expected to match or beat the lowest prices offered in other developed countries. If companies fail to make meaningful progress toward those pricing targets within 30 days, the order instructs the Secretary of Health and Human Services to propose a formal rule-making plan. That plan would aim to bring U.S. drug prices closer to international standards.

Health policy experts told KFF Health News that the order serves more as a pressure tactic than an immediate solution. The legal authority for the executive branch to impose pricing rules is uncertain, so the effectiveness of the order may rely more on its political weight than enforceable law. Even if the administration moves forward with a formal rule, the timeline for implementing such a plan would likely take months or even years, given the complex federal rule-making process.

Still, the issue of high drug costs remains a rare area of agreement across party lines. Lawmakers from both sides of the aisle have voiced concerns about the fairness of current pricing models. According to research from the Rand Corporation, U.S. prescription drug prices are, on average, 2.78 times higher than in other industrialized nations. For brand-name drugs, the difference is even greater, 4.22 times higher on average.

With so much at stake for patients, the administration’s move is being closely watched. While immediate price cuts are unlikely, the executive order signals growing political pressure on drug manufacturers and regulators to find ways to ease the financial burden on consumers.